Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of clinical research vials and bladder cancer diagnostics, reflecting ImmunityBio’s Tokyo-172 BCG agreement with Japan BCG Laboratory and its potential role in easing the long-running U.S. BCG supply shortage for non-muscle invasive bladder cancer treatment.
Pharma & Biotech

Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply

A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.

Read More
Representative image: Generic semaglutide injection pens on a clinical desk with Canadian healthcare cues, reflecting Dr. Reddy’s Laboratories’ launch of generic semaglutide injection in Canada and the growing focus on GLP-1 access for type 2 diabetes treatment.
Pharma & Biotech

Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?

GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.

Read More
Representative image: An oncologist reviews breast cancer imaging with a patient in a clinical setting, reflecting how AstraZeneca and Daiichi Sankyo’s ENHERTU approval could reshape treatment options for HER2-positive early breast cancer.
Pharma & Biotech

ENHERTU enters curative-intent breast cancer care as FDA widens AstraZeneca and Daiichi Sankyo label

ENHERTU is moving earlier in breast cancer care. The bigger question is whether efficacy gains can outweigh ADC safety scrutiny.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Can United Therapeutics turn pig-heart xenotransplantation into a regulated clinical pathway?

A pig-heart trial is no longer just a scientific leap. United Therapeutics now faces the harder test of safety, scale, and regulation.

Read More
Representative image of an oncology consultation as Imfinzi moves toward becoming the first NHS immunotherapy option for eligible stomach cancer patients in England, marking a potential shift in gastric cancer treatment pathways.
Pharma & Biotech

AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer

Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.

Read More
Representative image: A clinician reviews prescribing and dosing data for an injectable rare disease therapy, reflecting Kyowa Kirin’s FDA-approved Crysvita dosing update for adults with X-linked hypophosphatemia.
Pharma & Biotech

What Kyowa Kirin’s Crysvita dosing change reveals about rare disease treatment individualisation

Rare disease dosing is becoming more personalised. Kyowa Kirin’s Crysvita update tests how far flexibility can improve adult XLH care.

Read More
Pharma & Biotech

Can Assertio give Zydus a faster route into U.S. specialty oncology care?

Zydus gets a U.S. oncology platform, but Rolvedon concentration risk will decide whether the Assertio deal becomes strategic or merely opportunistic.

Read More
Pharma & Biotech

Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy

UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.

Read More
Pharma & Biotech

How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care

Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.

Read More
Pharma & Biotech

Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America

Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.

Read More